Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT)

Romiti, Ricardo; Fabricio, L; Souza, Cacilda da Silva; Galvão, Leticia Oba; Castro, Caio César Silva de; Terena, Aripuanã Cobério; Carneiro, Francisca Regina Oliveira; Oyafuso, Luiza Keiko; Carneiro, Sueli; Kobata, Clarice Marie; Oliveira, Maria de Fátima; Cestari, Tania F.; Antônio, Joäo Roberto; Martins, Gisele; Marques, Sílvio Alencar; Chaibub, Sulamita Costa Wirth; Arruda, Ana Carolina Belini Bazán; Felix, Paulo Antônio Oldani; Magalhães, Renata Ferreira; Abulafia, Luna Azulay; Ferreira, Kuitéria Ribeiro; Silva, Aline Medeiros da; Silva, Bruno Leonardo; Souza, Juliano Luiz de

doi:10.1080/09546634.2018.1466023

Cited by 17 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously documented, achieving complete or almost complete skin clearance has strong associations with HRQoL [11,[23][24][25][26][27][28]. Of interest for the present study was whether this sustained level of skin clearance was associated with an equally sustained level of HRQoL.…”

Section: Discussionmentioning

confidence: 52%

“…Indeed, improvements in HRQoL are related to improvements in pain and itching, alongside improvements in skin clearance [12,23]. The extent of skin clearance also dictates the relationship with HRQoL: patients who achieve complete skin clearance have greater HRQoL improvements [11,[24][25][26][27][28]. Within our study, skin clearance and HRQoL were correlated during the sustained response period, in which patients had PASI scores indicative of near complete skin clearance.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab

Houghton¹,

Patil

Gómez

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Patients with psoriasis (PsO) experience impaired health-related quality of life due to physical and psychosocial burdens. The objective of this study was to assess the correlation between change in Psoriasis Area and Severity Index (PASI) score and selected Dermatology Life Quality Index (DLQI) domain scores in patients with moderate-to-severe PsO and those with PsO and comorbid psoriatic arthritis (PsA). Methods: This post hoc analysis of four phase 3 clinical trials included patients with moderateto-severe PsO randomized to secukinumab 150/300 mg, etanercept, or placebo. Pairwise latent growth models were applied to assess the longitudinal correlation between change in PASI scores and changes in three DLQI domain scores (daily activities, leisure activities, and symptoms/feelings). The initial (baseline to week 12) and sustained (week[ 12 to week 52) treatment exposures were analysed by population type (total, PsO only, and PsO with comorbid PsA) and treatment arm (secukinumab, etanercept, or placebo). Results: Among the total population (N = 2401), PASI change was positively correlated with change in each assessed DLQI domain; correlations were weak to moderate over the initial treatment exposure period (b range, 0.20-0.29; all P \ 0.001) and moderate to strong over the sustained exposure period (b range, 0.63-0.69; all P \ 0.001). Similar trends were observed regardless of the presence of comorbid PsA. These relationships were confirmed among patients treated with secukinumab, etanercept, or placebo. Conclusions: Improvements in PASI scores were directly moderately related to improvements in DLQI domain scores from initiation of treatment and extended over time, regardless of presence of comorbid PsA or treatment received.

show abstract

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 85%

Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab

Houghton¹,

Patil

Gómez

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…In 1978, the Psoriasis Area and Severity Index (PASI) was created to determine the effects of retinoids on psoriasis and has gained worldwide use to quantify the severity of the disease according to the extent affected and clinical parameters. Because it is a clinimetric instrument, which does not depend on the patient's subjectivity, but on clinical manifestations evaluated by the doctor, it did not go through stages of cultural adaptation for use in Brazil, nor in any of the countries that use it (Fredriksson & Pettersson, 1978; Romiti, 2010; Romiti et al, 2018).…”

Section: Methodsmentioning

confidence: 99%

“…In a Brazilian study, with 1125 participants, 53% of them had some psychological comorbidities, being 39.7% of anxiety and 27.1% of depression (Romiti et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Prevalence and factors associated with depression and anxiety in patients with psoriasis

Pollo

Miot

Matos

et al. 2020

Journal of Clinical Nursing

View full text Add to dashboard Cite

Objective To identify the prevalence and factors associated with depression and anxiety in patients with psoriasis. Background Psoriasis is a chronic, non‐contagious, autoimmune inflammatory skin disease associated with psychological comorbidities. Design A cross‐sectional study conducted between March 2017–December 2018 in a dermatology infirmary and outpatient clinic of a public hospital in the inner State of São Paulo (Brazil). Methods We used questionnaires with sociodemographic data and clinical history, the HADS (Hospital Anxiety and Depression Scale), DLQI‐BRA (Dermatology Life Quality Index) and PASI (Psoriasis Area Severity Index). The correlations between variables were explored using multivariate techniques. STROBE checklist was applied as the reporting guideline for this study (File S1). Results A total of 281 participants were included, of which the majority were female 146 (52%), with a mean age of 52.1 years (SD: 13.8), elementary school 154 (55%), married/cohabiting 209 (74%) and with low income 201 (72%). The median (p25–p75) time with the disease was 14 years (7–23). Regarding the quality of life, 31% of respondents reported being little affected by the disease. The prevalence of depression was 19% and that of anxiety was 36%. The multivariate analysis showed that the variables that influenced the anxiety and depression scores were as follows: DLQI‐BRA, income, female sex, illness length and age. For the multiple correspondence analysis, the highest levels of anxiety and depression referred to women, middle age, lower income and low PASI. Conclusion The prevalence of anxiety and depression symptoms was low. Female sex, income, age, illness length and quality of life were associated with anxiety and depression scores in patients with psoriasis. Relevance to clinical practice Due to the scarcity of studies in the field of nursing with psoriasis patients, we believe these findings contribute to the reorganisation of the care provided, allowing nurses to timely identify mood disorders such as anxiety and depression and adopt the necessary measures to a service and/or specialised referral.

show abstract

“…Psoriasis is an immune-mediated, chronic, inflammatory disease, which usually affects skin but also can affect joints and nails [1–3]. Worldwide estimates of the prevalence of psoriasis range from 0.51% to 11.43% in adults and from 0% to 1.37% in children [4].…”

Section: Introductionmentioning

confidence: 99%

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Lopes¹,

Dias

Azulay‐Abulafia³

et al. 2019

Adv Ther

Self Cite

View full text Add to dashboard Cite

IntroductionPsoriasis is an immune-mediated, chronic, inflammatory disease, which has a substantial humanistic and economic burden. This study aimed to assess the impact of this disease on health-related quality of life (HRQoL), work productivity, and direct and indirect costs from a societal perspective among Brazilian patients.MethodsThis is a cross-sectional, observational, multicenter study, enrolling patients with moderate to severe plaque psoriasis according to physician evaluation. Data collection was performed from December 2015 to November 2016 through face-to-face interviews using a structured questionnaire and five standardized patient-reported outcomes instruments. Direct costs were estimated by multiplying the amount of resources used (12-month recall period) by the corresponding unit cost. Indirect costs were grouped in two time horizons: annual costs (income reduction and absenteeism) and lifetime costs (demission and early retirement).ResultsA total of 188 patients with moderate to severe plaque psoriasis were included, with mean age of 48.0 (SD 13.1). “Anxiety and depression” and “pain and discomfort” were the most impaired dimensions, according to the EuroQol Five-Dimension-Three-Level (EQ-5D-3L). The highest effect was found for “symptoms and feelings” [mean (SD) 2.4 (1.7)] Dermatology Life Quality Index (DLQI) subscale. Psoriatic arthritis (PsA) presence and biologic-naïve status were associated with worse HRQoL. Presenteeism was more frequent than absenteeism, according to the Work Productivity and Activity Impairment questionnaire-General Health (WPAI-GH) [17.4% vs. 6.3%], while physical demands and time management were the most affected Work Limitations Questionnaire (WLQ) subscales [means (SD) 23.5 (28.5) and 17.7 (24.9), respectively]. The estimated annual cost per patient was USD 4034. Direct medical costs accounted for 87.7% of this estimate, direct non-medical costs for 2.4%, and indirect costs for 9.9%.ConclusionsResults evidenced that moderate to severe plaque psoriasis imposes substantial costs to society. Our data showed that this disease negatively affects both work productivity and HRQoL of Brazilian patients. Subgroups with PsA and biologic-naïve patients presented lower HRQoL, showing the impact of this comorbidity and the relevance of biologics in psoriasis treatment.FundingNovartis Biociências S.A.Electronic supplementary materialThe online version of this article (10.1007/s12325-019-01049-7) contains supplementary material, which is available to authorized users.

show abstract

Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT)

Abstract: Among Brazilian patients with moderate-to-severe psoriasis, disease severity had far-reaching adverse impacts on lifestyle, comorbidities, HRQOL, and work productivity.

Cited by 17 publications

References 34 publications

Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab

Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab

Prevalence and factors associated with depression and anxiety in patients with psoriasis

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Contact Info

Product

Resources

About